Is InterCure Ltd. (INCR) a Buy, Sell, or Hold?
NASDAQ : INCR
InterCure Ltd.
$0.9598 USD
$0.05 (5.8%)
- Volume
- 10.23K
- Average Volume
- 56.62K
- Market Capitalization
- $54.85M
- P/E Ratio
- -4.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.77
- Year Low
- $0.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.48
Company Overview
NASDAQ
Alexander Rabinovich
Drug Manufacturers - Specialty & Generic
Healthcare
INCR
285
IL
USD
Liquidity Metrics
0.46
1.48
0.97
0.22
0.00
Sales & Valuation
$270.2M
0.61
0.37
12.40
0.26
Profitability
-$0.63
-$35.71M
-13.22%
-16.32%
-8.63%
-5.17%
P/E Metrics
-4.06
-0.06
-0.06
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-0.06
4/9
$102.38M
$690.55M
$294.2M
-$67.24M
Key Metrics (TTM)
$301.77M
1.12
-5.45
1.48
-8.63%
-4.70%
-24.37%
8.04%
272 days
Company Executives
| Name | Title |
|---|---|
| Itai Kabiljo | General Counsel |
| Amos Cohen | Chief Financial Officer |
| Einat Zehavi | Vice President of Sales |
| Alexander Rabinovich | Chief Executive Officer & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About InterCure Ltd. (NASDAQ:INCR) Stock
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel. ...
2026-06-22 08:50:00
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 million (approximately US$18.6 million) (the “Private Placement”).
2026-06-15 09:25:00
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U. S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U. S. Medical Cannabis Markets.
2026-06-15 09:25:00
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
2026-04-30 18:05:00
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
2026-04-30 18:05:00
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd.
Frequently Asked Questions
-
What is the current InterCure Ltd. (INCR) stock price?
-
InterCure Ltd.(NASDAQ:INCR) stock price is $0.9598 in the last trading session. During the trading session, INCR stock reached the peak price of $1.77 while $0.68 was the lowest point it dropped to. The percentage change in INCR stock occurred in the recent session was 5.8% while the dollar amount for the price change in INCR stock was $0.05.
-
INCR's industry and sector of operation?
-
The NASDAQ listed INCR is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of INCR?
-
Itai Kabiljo | General Counsel
Amos Cohen | Chief Financial Officer
Einat Zehavi | Vice President of Sales
Alexander Rabinovich | Chief Executive Officer & Chairman
| -
How many employees does INCR have?
-
Number of INCR employees currently stands at 285. INCR operates from 85 Medinat ha-Yehudim Street, Herzliya, TA 4676670, IL.
-
Link for INCR official website?
-
Official Website of INCR is: https://www.intercure.co
-
How do I contact INCR?
-
INCR could be contacted at phone #972 7 7460 5012 and can also be accessed through its website. INCR operates from 85 Medinat ha-Yehudim Street, Herzliya, TA 4676670, IL.
-
How many shares of INCR are traded daily?
-
The average number of INCR shares traded daily for last 3 months was 56.62K.
-
What is the market cap of INCR currently?
-
The market value of INCR currently stands at $54.85M with its latest stock price at $0.9598